GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B1903 Carbazochrome sodium sulfonate (AC-17)Target: Deubiquitinating enzymes (DUBs)Summary: antihemorrhagic agent -
B1351 Xylazine HClSummary: α2 Adrenoceptor agonist -
B1367 SotalolSummary: Adrenergic receptor antagonist -
B2116 Ozagrel HClSummary: Potent and selective inhibitor of thromboxane (TXA2) synthetase -
B1357 Dexmedetomidine HClSummary: Highly selective and potent alpha-2 adrenoceptor agonist -
B1348 Salbutamol SulfateSummary: β-2 adrenergic receptor agonist -
B1340 Naphazoline HClSummary: Adrenergic receptor agonist -
B1683 Brimonidine TartrateSummary: Highly selective α-adrenergic receptor agonist -
B1346 Propranolol HClSummary: Competitive non-selective beta-adrenergic receptors inhibitor -
B1342 Oxymetazoline HClSummary: Alpha-1/alpha-2 agonist

